| Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma L De Mattos-Arruda, R Mayor, CKY Ng, B Weigelt, F Martínez-Ricarte, ... Nature communications 6 (1), 8839, 2015 | 739 | 2015 |
| The Hippo effector YAP promotes resistance to RAF-and MEK-targeted cancer therapies L Lin, AJ Sabnis, E Chan, V Olivas, L Cade, E Pazarentzos, S Asthana, ... Nature genetics 47 (3), 250-256, 2015 | 529 | 2015 |
| Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients N Karachaliou, M Gonzalez-Cao, G Crespo, A Drozdowskyj, E Aldeguer, ... Therapeutic advances in medical oncology 10, 1758834017749748, 2018 | 251 | 2018 |
| Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis M Duruisseaux, A Martínez-Cardús, ME Calleja-Cervantes, S Moran, ... The Lancet Respiratory Medicine 6 (10), 771-781, 2018 | 184 | 2018 |
| Human endogenous retroviruses and cancer M Gonzalez-Cao, P Iduma, N Karachaliou, M Santarpia, J Blanco, ... Cancer biology & medicine 13 (4), 483, 2016 | 179 | 2016 |
| Circulating melanoma exosomes as diagnostic and prognosis biomarkers E Alegre, L Zubiri, JL Perez-Gracia, M González-Cao, L Soria, ... Clinica chimica acta 454, 28-32, 2016 | 166 | 2016 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 163 | 2022 |
| Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case–control study D Massi, S Puig, A Franchi, J Malvehy, S Vidal-Sicart, M González-Cao, ... Journal of clinical pathology 59 (2), 166-173, 2006 | 142 | 2006 |
| Liquid biopsy for lung cancer early detection M Santarpia, A Liguori, A D’Aveni, N Karachaliou, M Gonzalez-Cao, ... Journal of thoracic disease 10 (Suppl 7), S882, 2018 | 125 | 2018 |
| Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients U Malapelle, C Mayo de-Las-Casas, D Rocco, M Garzon, P Pisapia, ... British Journal of Cancer 116 (6), 802-810, 2017 | 125 | 2017 |
| Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions C Mayo-de-Las-Casas, N Jordana-Ariza, M Garzón-Ibañez, A Balada-Bel, ... Annals of Oncology 28 (9), 2248-2255, 2017 | 110 | 2017 |
| Immune checkpoint inhibitors: therapeutic advances in melanoma I Marquez-Rodas, P Cerezuela, A Soria, A Berrocal, A Riso, ... Annals of translational medicine 3 (18), 2015 | 110 | 2015 |
| Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy M Santarpia, A Liguori, N Karachaliou, M Gonzalez-Cao, MG Daffinà, ... Lung Cancer: Targets and Therapy, 109-125, 2017 | 91 | 2017 |
| BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors M Gonzalez-Cao, C Mayo-De-Las-Casas, MA Molina-Vila, ... Melanoma research 25 (6), 486-495, 2015 | 89 | 2015 |
| Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types L Paré, T Pascual, E Seguí, C Teixidó, M Gonzalez-Cao, P Galván, ... Annals of Oncology 29 (10), 2121-2128, 2018 | 85 | 2018 |
| Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study M Gonzalez-Cao, T Morán, J Dalmau, J Garcia-Corbacho, JWP Bracht, ... JAMA oncology 6 (7), 1063-1067, 2020 | 81 | 2020 |
| Advances in immunotherapy for treatment of lung cancer JGB Alvarez, M González-Cao, N Karachaliou, M Santarpia, S Viteri, ... Cancer biology & medicine 12 (3), 209, 2015 | 78 | 2015 |
| Liquid biopsy in non-small cell lung cancer MA Molina-Vila, C Mayo-De-las-Casas, A Gimenez-Capitan, ... Frontiers in medicine 3, 69, 2016 | 75 | 2016 |
| Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions S Villatoro, C Mayo‐de‐las‐Casas, N Jordana‐Ariza, S Viteri‐Ramírez, ... Molecular oncology 13 (12), 2633-2645, 2019 | 72 | 2019 |
| The combination of checkpoint immunotherapy and targeted therapy in cancer N Karachaliou, M Gonzalez-Cao, A Sosa, J Berenguer, JWP Bracht, M Ito, ... Annals of translational medicine 5 (19), 2017 | 71 | 2017 |
